Portfolio

Company Announcements

New CE mark granted for Silhouette Soft

Related Companies

By LSE RNS

RNS Number : 1138U
Sinclair Pharma PLC
19 October 2017
 

 

 

Sinclair Pharma plc

 

New CE mark granted for Silhouette Soft® 

 

 

London, 19 October 2017 Sinclair Pharma plc (SPH.L), ("Sinclair") the international aesthetics company, is pleased to announce that Silhouette Soft® has been re-issued a European CE mark, effective immediately.

 

As previously disclosed by Sinclair, the de-designation of a number of European Notified Bodies affected the registrations of numerous medical devices across the industry, including Silhouette Soft®. The dossier for Silhouette Soft® has been reviewed and relevant audits completed to the satisfaction of the Group's new Notified Body. The CE mark renewal process did not affect supply of Silhouette Soft® and sales under the new CE mark can commence immediately.

 

 

 

For further information please contact:

Sinclair Pharma plc

Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Andy Crane


 

Peel Hunt LLP (NOMAD and Joint Broker)

Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson


 

RBC Capital Markets (Joint Broker)

Tel: +44 (0) 20 7653 4000

Marcus Jackson

Laura White


 

Media enquiries

FTI Consulting

Tel: +44 (0) 203 727 1000

Ben Atwell

Brett Pollard

Stephanie Cuthbert


 

 

Notes to Editors:

 

About Sinclair Pharma plc 

Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors.

 

For more information, please visit

 

www.sinclairpharma.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGGWPUUPMGWB

Top of Page